Regenxbio Inc (RGNX)
17.03
-0.47
(-2.69%)
USD |
NASDAQ |
Apr 17, 16:00
17.03
0.00 (0.00%)
After-Hours: 20:00
Regenxbio Enterprise Value: 582.12M for April 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 16, 2024 | 582.12M |
| April 15, 2024 | 607.59M |
| April 12, 2024 | 611.02M |
| April 11, 2024 | 656.59M |
| April 10, 2024 | 648.26M |
| April 09, 2024 | 656.10M |
| April 08, 2024 | 664.91M |
| April 05, 2024 | 663.93M |
| April 04, 2024 | 662.95M |
| April 03, 2024 | 716.85M |
| April 02, 2024 | 718.81M |
| April 01, 2024 | 779.56M |
| March 28, 2024 | 757.02M |
| March 27, 2024 | 811.40M |
| March 26, 2024 | 786.42M |
| March 25, 2024 | 782.50M |
| March 22, 2024 | 791.81M |
| March 21, 2024 | 827.08M |
| March 20, 2024 | 827.57M |
| March 19, 2024 | 821.69M |
| March 18, 2024 | 818.75M |
| March 15, 2024 | 811.89M |
| March 14, 2024 | 795.23M |
| March 13, 2024 | 825.61M |
| March 12, 2024 | 801.60M |
| Date | Value |
|---|---|
| March 11, 2024 | 844.23M |
| March 08, 2024 | 735.47M |
| March 07, 2024 | 756.80M |
| March 06, 2024 | 791.00M |
| March 05, 2024 | 818.11M |
| March 04, 2024 | 673.72M |
| March 01, 2024 | 666.16M |
| February 29, 2024 | 499.56M |
| February 28, 2024 | 608.85M |
| February 27, 2024 | 614.18M |
| February 26, 2024 | 539.54M |
| February 23, 2024 | 498.23M |
| February 22, 2024 | 531.99M |
| February 21, 2024 | 535.19M |
| February 20, 2024 | 541.36M |
| February 16, 2024 | 554.13M |
| February 15, 2024 | 537.39M |
| February 14, 2024 | 464.28M |
| February 13, 2024 | 431.24M |
| February 12, 2024 | 489.38M |
| February 09, 2024 | 438.73M |
| February 08, 2024 | 442.25M |
| February 07, 2024 | 366.50M |
| February 06, 2024 | 299.54M |
| February 05, 2024 | 267.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
260.78M
Minimum
Jan 30 2024
1.716B
Maximum
Apr 18 2019
906.14M
Average
940.73M
Median
Oct 30 2019
Enterprise Value Benchmarks
| Sarepta Therapeutics Inc | 10.56B |
| Amgen Inc | 196.06B |
| Gilead Sciences Inc | 101.50B |
| AbbVie Inc | 333.73B |
| Bristol-Myers Squibb Co | 125.14B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.89M |
| Revenue (Quarterly) | 22.21M |
| Total Expenses (Quarterly) | 86.12M |
| EPS Diluted (Quarterly) | -1.42 |
| Gross Profit Margin (Quarterly) | 49.41% |
| Profit Margin (Quarterly) | -283.1% |
| Earnings Yield | -35.35% |
| Normalized Earnings Yield | -36.87 |